A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer (The NEO trial)

Status:

Recruiting

Phase

2nd+

Line of Therapy

Relapsed / Recurrent / Refractory

Disease Stage

Biomarker(s)

N/A

Investigational

Product

Olaparib

VEGFR tyrosine kinase inhibitor (p.o.)

Treatment Arms

o Experimental: Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery

o Experimental: Olaparib Prior to Surgery and Post Surgery